Werkgroep Cardiologische centra Nederland

SPIRIT-HF (Follow-up)

Double-blind, randomized, placebo-controlled, parallel group, interventional phase III study to evaluate efficacy and safety of spironolactone compared to placebo on composite endpoint of recurrent HF hospitalizations and CV death in patients with HF with mid- range or preserved ejection fraction
Medicine
Spironolacton
Population
Heart failure
Phase
IV
Starting year
2018